Hu, Jiali
Lu, Ruitao
Zhang, Yu
Li, Wei
Hu, Qian
Chen, Cuiyu
Liu, Zhaoqian
Zhang, Wei
Chen, Ling
Xu, Ran
Luo, Jia
McLeod, Howard L.
He, Yijing https://orcid.org/0000-0001-5831-641X
Funding for this research was provided by:
the National Natural Science Foundation of China (Grant No. No.81773821, 82173906)
Chinese National Major Project for New Drug Innovation (2019ZX09201-002-006)
the National Key Research and Development Program (No. 2016YFC0905000)
the Fundamental Research Funds for the Central Universities of Central South University (No.198101066, No.208111176)
the key project of health commission of Hunan Province (202113010141)
the Natural Science Foundation of Hunan Province, China (2021JJ31063, 2021JJ31044, 2019JJ40477)
Article History
Received: 23 June 2021
Accepted: 7 September 2021
First Online: 20 September 2021
Declarations
:
: The animal study protocol was approved by the Ethics Committee of Xiangya Hospital, Central South University (No. 2020sydw0167) and all experiments were performed in accordance with approved guidelines of Xiangya Hospital, Central South University.
: Not applicable.
: Prof McLeod is on the board of directors for Vyant Bio. He is one of the founders of Clariifi LLC and a consultant to Viecure and eviCORE Health Solutions. All other authors declared no competing interests for this work.